Submit NDA for DARE-BV1 to the FDA
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“planned NDA submission 1H 2021”
What we found
Evidence strength A What the grades mean
The company successfully submitted the NDA for DARE-BV1 to the FDA in June 2021, meeting its commitment to submit within the first half of 2021.
-
A Dare Bioscience, Inc. 10-Q filed 2021-11-10
“When we submitted the DARE-BV1 NDA to the FDA in June 2021” ✓ confirmed on the page
Market reaction: the shares moved -1.2% against the S&P 500 over the three sessions around the disclosure (9 Nov 2021 to 12 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA submission for DARE-BV1
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Dare Bioscience, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DARE-021720 · Corrections policy